JP7617043B2 - ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法 - Google Patents

ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法 Download PDF

Info

Publication number
JP7617043B2
JP7617043B2 JP2021576883A JP2021576883A JP7617043B2 JP 7617043 B2 JP7617043 B2 JP 7617043B2 JP 2021576883 A JP2021576883 A JP 2021576883A JP 2021576883 A JP2021576883 A JP 2021576883A JP 7617043 B2 JP7617043 B2 JP 7617043B2
Authority
JP
Japan
Prior art keywords
compound
crystalline form
solid
peaks
exemplary embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539342A5 (enExample
JP2022539342A (ja
Inventor
シャオダ ユアン
シャオシン フェン
ダニー ティー ディン
ウィリアム アール ペロー
Original Assignee
ノーレックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノーレックス インコーポレイテッド filed Critical ノーレックス インコーポレイテッド
Publication of JP2022539342A publication Critical patent/JP2022539342A/ja
Publication of JP2022539342A5 publication Critical patent/JP2022539342A5/ja
Priority to JP2025001914A priority Critical patent/JP2025069143A/ja
Application granted granted Critical
Publication of JP7617043B2 publication Critical patent/JP7617043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021576883A 2019-06-24 2020-06-23 ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法 Active JP7617043B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025001914A JP2025069143A (ja) 2019-06-24 2025-01-06 ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24
US62/865,826 2019-06-24
PCT/US2020/039163 WO2020263847A1 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025001914A Division JP2025069143A (ja) 2019-06-24 2025-01-06 ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法

Publications (3)

Publication Number Publication Date
JP2022539342A JP2022539342A (ja) 2022-09-08
JP2022539342A5 JP2022539342A5 (enExample) 2023-06-30
JP7617043B2 true JP7617043B2 (ja) 2025-01-17

Family

ID=74060350

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576883A Active JP7617043B2 (ja) 2019-06-24 2020-06-23 ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
JP2025001914A Pending JP2025069143A (ja) 2019-06-24 2025-01-06 ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025001914A Pending JP2025069143A (ja) 2019-06-24 2025-01-06 ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法

Country Status (11)

Country Link
US (1) US20220267341A1 (enExample)
EP (1) EP3986399A4 (enExample)
JP (2) JP7617043B2 (enExample)
CN (1) CN114364380A (enExample)
AU (1) AU2020304001B2 (enExample)
BR (1) BR112021026380A2 (enExample)
CA (1) CA3144600A1 (enExample)
IL (1) IL289198A (enExample)
MA (1) MA56550A (enExample)
MX (2) MX2022000069A (enExample)
WO (1) WO2020263847A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4484431A3 (en) * 2019-06-24 2025-03-26 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120786A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2020263848A1 (en) 2019-06-24 2020-12-30 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
ES2416354T3 (es) * 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
PE20151416A1 (es) * 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
DK3436463T3 (da) * 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120786A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2020263848A1 (en) 2019-06-24 2020-12-30 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Also Published As

Publication number Publication date
WO2020263847A1 (en) 2020-12-30
AU2020304001B2 (en) 2026-04-09
JP2025069143A (ja) 2025-04-30
MX2022000069A (es) 2022-05-24
MA56550A (fr) 2022-04-27
US20220267341A1 (en) 2022-08-25
KR20220061088A (ko) 2022-05-12
CA3144600A1 (en) 2020-12-30
EP3986399A4 (en) 2023-06-07
JP2022539342A (ja) 2022-09-08
IL289198A (en) 2022-02-01
AU2020304001A1 (en) 2022-01-27
CN114364380A (zh) 2022-04-15
MX2025002579A (es) 2025-04-02
BR112021026380A2 (pt) 2022-05-10
EP3986399A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
JP2025069143A (ja) ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
US11584715B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
CA3088356A1 (en) Crystal forms and production methods thereof
KR102958083B1 (ko) 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
JP7776258B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
KR20260061467A (ko) 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
EA044016B1 (ru) Твердые формы трет-бутил(s)-2-((2s,3r)-1-амино-3-гидрокси-1-оксобутан-2-ил)-1-оксо-2,5-диазаспиро[3.4]октан-5-карбоксилата и способы их получения
WO2011029005A1 (en) Crystalline forms of fesoterodine fumarate and fesoterodine base
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
TW202541790A (zh) 馬立馬司他之結晶多晶型、馬立馬司他之非晶質型、其製備的製程、包含其之藥物組成物及其用途
CA2989364C (en) Process for the preparation of enclomiphene citrate having needle shaped crystal habit.
JP2025533955A (ja) （２ｓ，５ｒ）－５－（２－クロロフェニル）－１－（２’－メトキシ－［１，１’－ビフェニル］－４－カルボニル）ピロリジン－２－カルボン酸の多形およびその調製プロセス
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
CA2902436C (en) Salt of omecamtiv mecarbil and process for preparing salt
TW202332440A (zh) 神經激肽-1拮抗劑前藥化合物的晶型
HK40035144B (zh) 两种化合物的制备方法
HK40037540A (en) Crystal forms and production methods thereof
HK40037540B (en) Crystal forms and production methods thereof
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt
JP2012500192A (ja) １−イソプロピル−４−｛［４−（テトラヒドロ−２ｈ−ピラン−４−イルオキシ）フェニル］カルボニル｝ヘキサヒドロ−１ｈ−１，４−ジアゼピンの塩およびその調製方法
HK1159095A (en) Synthesis and novel salt forms of (r)-5-(e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617043

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150